



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
11134-019-999	10/789,165
APPLICANT	
Collins et al.	
FILING DATE	GROUP 1624
February 26, 2004	To be assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CMD	A01	2002/0169159 A1	11/02	Medina et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
CMD	A02	WO01/16114	3/01	PCT					
↓	A03	WO01/30768	5/01	PCT					
↓	A04	WO01/98278	12/01	PCT					

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**


EXAMINER	<i>Cecilia Juile</i>	DATE CONSIDERED	<i>9/14/06</i>
----------	----------------------	-----------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 12 2005

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
11134-019-999	10/789,165

APPLICANT
Collins, et al.

FILING DATE	GROUP
February 26, 2004	1614-1624

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CMJ	B01	5,202,322	4/13/93	Allen et al.			
	B02	5,256,667	10/26/93	Allen et al.			
	B03	5,719,144	2/17/98	Hartman et al.			
	B04	5,756,502	5/26/98	Padia			
	B05	5,869,665	2/9/99	Padia			
	B06	5,908,930	6/1/99	Dow			
	B07	6,140,064	10/31/00	Loetscher et al.			
	B08	6,545,005	4/8/03	Baxter et al.			
	B09	6,605,632	8/12/03	Lesieur et al.			
	B10	6,794,379	9/21/04	Medina et al.			
↓	B11	20030134843	7/17/03	Lubisch et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
CMJ	B12	International Search Report of PCT/US01/47850	8/26/02	PCT				→	
	B13	International Search Report of PCT/US04/05960	10/12/04	PCT				→	
	B14	EP 0481 614 A1	4/22/92	EPO				→	
	B15	WO92/01675	2/6/92	PCT				→	
	B16	WO97/04775	2/13/97	PCT				→	
	B17	WO98/13350	4/2/98	PCT				→	
	B18	WO98/26664	6/25/98	PCT				→	
	B19	WO99/58495	11/18/95	PCT				→	
	B20	WO01/057038	8/9/01	PCT				→	
	B21	WO01/19800 A2	3/22/01	PCT				→	
	B22	WO01/19800 A3	3/22/01	PCT				→	
	B23	WO01/62758	8/30/01	PCT				→	
	B24	WO01/77087	10/18/01	PCT				→	
	B25	WO02/28831	4/11/02	PCT				→	
↓	B26	WO02/083143	10/24/02	PCT				→	

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

CMJ	B27	Agostini, et al., 1998 "Involvement of the IP-10 Chemokine in Sarcoid Granulomatous Reactions", <i>J. Immunol.</i> 161: 6413-6420.
-----	-----	--

<i>CMJ</i>	B28	Balashov <i>et al.</i> , 1999 "CCR5 <sup>+</sup> and CXCR3 <sup>+</sup> T Cells are Increased in Multiple Sclerosis and Their Ligands MIP-1 $\alpha$ and IP-10 are Expressed in Demyelinating Brain Lesions," Proc. Natl. Acad. Sci. USA, 96:6873-78.
	B29	Banker, <i>et al.</i> , 1996 "Prodrugs", <i>Modern Pharmaceutics</i> , 3ed" Marcel Dekker, New York 596.
	B30	Bowdish <i>et al.</i> 2003 "Evaluation of An Oral CXCR3 Antagonist in a Rat Model of the Acute Allograft Rejection", <i>The Journal of the Heart and Lung Association</i> Vol. 22 Supplement 1 Page S162
	B31	Carter, <i>et al.</i> , 2002 "Chemokine Receptor Antagonism as an Approach to Anti-Inflammatory Therapy: 'Just Right' or Plain Wrong?", <i>Current Opin. Chem. Biol.</i> , 6: 510-525.
	B32	Cecil's Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 1 (a996), pages 1004-1010 (1996)
	B33	Cecil's Textbook of Medicine, 20 <sup>th</sup> Edition, Vol. 2, pages 1992-96 (1996)
	B34	Chabrier <i>et al.</i> Pubmed Abstract 10442086, also cited as Cell. Mol. Life Sci. 55/8-9 1029-35 (1999)
	B35	Chiang <i>et al.</i> , Pubmed Abstract 12898413, also cited as Planta Med., 69/7, 600-4, (2003)
	B36	J.T. Coyle <i>et al.</i> , 1983 Science 219, 1184-90
	B37	Fife <i>et al.</i> , 2001 "CXCL10 (IFN- $\gamma$ -Inducible Protein-10) Control of Encephalitogenic CD4 <sup>+</sup> T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis", <i>J. Immunol.</i> 166: 7617-7624.
	B38	Gerard, <i>et al.</i> , 2001 "Chemokines and Diseases", <i>Nature Immunology</i> , 2(2): 108-115.
	B39	Goldbeerg <i>et al.</i> , 2001 Pubmed Abstract 11437993, also cited as Neuropathol. Appl. Neurobiol. 27/2, 127-38.
	B40	Hancock <i>et al.</i> , 2000 "Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection," <i>J. Exp. Med.</i> , 192(10):1515-19..
	B41	Hancock <i>et al.</i> , 2001 "Donor-Derived IP-10 Initiates Development of Acute Allograft Rejection", <i>J. Exp. Med.</i> 193: 975-980
	B42	Liang, <i>et al.</i> , 2000 "Identification and Characterization of a Potent Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1", <i>The J. of Biol. Chem.</i> . 25(23): 19000-19008.
	B43	Liu <i>et al.</i> , 2001 "Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis", <i>J. Immunol.</i> 167: 4091-4097.
	B44	Melter <i>et al.</i> , 2001 "Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Cardiac Allograft Rejection", <i>Circulation</i> 104: 2558-2564.
	B45	Onuffer, <i>et al.</i> , 2002 "Chemokines, Chemokine Receptors and Small-Molecule Antagonists: Recent Developments", <i>Trends in Pharmacological Sciences</i> 23(10): 459-467.
	B46	Padia, J.K., <i>et al.</i> , "Design and synthesis of novel nonpeptide CCK-B receptor antagonists," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 7, 8 April 1997, pp. 805-810.
	B47	Proudfoot, <i>et al.</i> , 2003 "Strategies for Chemokine Antagonists as Therapeutics", <i>Seminars in Immunology</i> . 15:57-65.
	B48	Qin <i>et al.</i> , 1998 "The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions," <i>J. Clin. Invest.</i> 101(4): 746-54.
	B49	Rabin <i>et al.</i> , 1999 "Chemokine Receptor Responses on T Cells Achieved Through Regulation of Both Receptor Expression and Signaling," <i>The Journal of Immunology</i> , 162: 3840-50.
	B50	Rottman <i>et al.</i> , 2001 "Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin $\alpha E\beta 7$ in the Pathogenesis of Psoriasis Vulgaris", <i>Lab. Invest.</i> 81(3): 335-347.
	B51	Ruschpler <i>et al.</i> , 2003 "High CXCR3 Expression in nSynovial Mast Cells Associated with CXCL9 and CXCL10 Expression in Inflammatory Synovial Tissues of Patients with Rheumatoid Arthritis", <i>Arthritis Res. Ther.</i> 5: R241-R252.
	B52	Sasaki <i>et al.</i> , November 2002 "Blockade of CXCL10 Protects Mice From Acute Colitis and Enhances Crypt Cell Survival", <i>Eur. J. Immunol.</i> 32: 3197-31205.
	B53	Shields, <i>et al.</i> , 1999 "Chemokine and Chemokine Receptor Interactions Provide a Mechanism for Selective T Cell Recruitment to Specific Liver Compartments with Hepatitis C-Infected Liver", <i>J. Immunol.</i> 163: 6236-6243.
	B54	Sorensen <i>et al.</i> , 1999 "Expression of Specific Chemokines and Chemokine Receptors in the Central Nervous System of Multiple Sclerosis Patients", <i>J. Clinical Invest.</i> 103: 807-815.
	B55	Uckun <i>et al.</i> , 2001 "Structure Based Design of Novel Anticancer Agents", <i>Current Cancer Drug Targets</i> , 1, 59-71
	B56	Wells, <i>et al.</i> , 1999 "Chemokine Receptors and Their Antagonists in Allergic Lung Disease" <i>Inflamm. Res.</i> , 48: 353-362.
	B57	Wolff, Manfred E. "Burger's Medicinal Chemistry, 5ed Part 1", John Wiley & Sons, 1995, Pages 975-977.
↓	B58	Zhao <i>et al.</i> , 2002 Pubmed Abstract 121133984, also cited as J. Immunol., 169/3 1556-60

EXAMINER

*Cecilia Juule*

DATE CONSIDERED

9-14-06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.